PON1 and neuroblastoma: However, some studies have found an increased rate of resistance to PON in either pre-clinical or clinical settings [8–10], and a similar finding may therefore be possible in neuroblastoma, in which the efficacy of PON emerged from both in vitro and in vivo pre-clinical assessments [11, 12].